Cargando…
Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines
BACKGROUND: Coronavirus disease 2019 (COVID-19) mRNA vaccines are associated with an increased risk of myocarditis using hospital discharge diagnoses as an outcome. The validity of these register-based diagnoses is uncertain. METHODS: Patient records for subjects < 40 years of age and a diagnosis...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Academia
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202079/ https://www.ncbi.nlm.nih.gov/pubmed/37223633 http://dx.doi.org/10.48101/ujms.v128.9290 |
_version_ | 1785045370503430144 |
---|---|
author | Gedeborg, Rolf Holm, Lennart Feltelius, Nils Sundström, Anders Eggers, Kai M Nurminen, Marja-Leena Grünewald, Maria Pihlström, Nicklas Zethelius, Björn Ljung, Rickard |
author_facet | Gedeborg, Rolf Holm, Lennart Feltelius, Nils Sundström, Anders Eggers, Kai M Nurminen, Marja-Leena Grünewald, Maria Pihlström, Nicklas Zethelius, Björn Ljung, Rickard |
author_sort | Gedeborg, Rolf |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID-19) mRNA vaccines are associated with an increased risk of myocarditis using hospital discharge diagnoses as an outcome. The validity of these register-based diagnoses is uncertain. METHODS: Patient records for subjects < 40 years of age and a diagnosis of myocarditis in the Swedish National Patient Register were manually reviewed. Brighton Collaboration diagnosis criteria for myocarditis were applied based on patient history, clinical examination, laboratory data, electrocardiograms, echocardiography, magnetic resonance imaging and myocardial biopsy. Poisson regression was used to estimate incidence rate ratios, comparing the register-based outcome variable to validated outcomes. Interrater reliability was assessed by a blinded re-evaluation. RESULTS: Overall, 95.6% (327/342) of cases registered as myocarditis were confirmed (definite, probable or possible myocarditis according to Brighton Collaboration diagnosis criteria, positive predictive value 0.96 [95% CI 0.93–0.98]). Of the 4.4% (15/342) cases reclassified as no myocarditis or as insufficient information, two cases had been exposed to the COVID-19 vaccine no more than 28 days before the myocarditis diagnosis, two cases were exposed >28 days before admission and 11 cases were unexposed to the vaccine. The reclassification had only minor impact on incidence rate ratios for myocarditis following COVID-19 vaccination. In total, 51 cases were sampled for a blinded re-evaluation. Of the 30 randomly sampled cases initially classified as either definite or probably myocarditis, none were re-classified after re-evaluation. Of the in all 15 cases initially classified as no myocarditis or insufficient information, 7 were after re-evaluation re-classified as probable or possible myocarditis. This re-classification was mostly due to substantial variability in electrocardiogram interpretation. CONCLUSION: This validation of register-based diagnoses of myocarditis by manual patient record review confirmed the register diagnosis in 96% of cases and had high interrater reliability. Reclassification had only a minor impact on the incidence rate ratios for myocarditis following COVID-19 vaccination. |
format | Online Article Text |
id | pubmed-10202079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Open Academia |
record_format | MEDLINE/PubMed |
spelling | pubmed-102020792023-05-23 Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines Gedeborg, Rolf Holm, Lennart Feltelius, Nils Sundström, Anders Eggers, Kai M Nurminen, Marja-Leena Grünewald, Maria Pihlström, Nicklas Zethelius, Björn Ljung, Rickard Ups J Med Sci Original Article BACKGROUND: Coronavirus disease 2019 (COVID-19) mRNA vaccines are associated with an increased risk of myocarditis using hospital discharge diagnoses as an outcome. The validity of these register-based diagnoses is uncertain. METHODS: Patient records for subjects < 40 years of age and a diagnosis of myocarditis in the Swedish National Patient Register were manually reviewed. Brighton Collaboration diagnosis criteria for myocarditis were applied based on patient history, clinical examination, laboratory data, electrocardiograms, echocardiography, magnetic resonance imaging and myocardial biopsy. Poisson regression was used to estimate incidence rate ratios, comparing the register-based outcome variable to validated outcomes. Interrater reliability was assessed by a blinded re-evaluation. RESULTS: Overall, 95.6% (327/342) of cases registered as myocarditis were confirmed (definite, probable or possible myocarditis according to Brighton Collaboration diagnosis criteria, positive predictive value 0.96 [95% CI 0.93–0.98]). Of the 4.4% (15/342) cases reclassified as no myocarditis or as insufficient information, two cases had been exposed to the COVID-19 vaccine no more than 28 days before the myocarditis diagnosis, two cases were exposed >28 days before admission and 11 cases were unexposed to the vaccine. The reclassification had only minor impact on incidence rate ratios for myocarditis following COVID-19 vaccination. In total, 51 cases were sampled for a blinded re-evaluation. Of the 30 randomly sampled cases initially classified as either definite or probably myocarditis, none were re-classified after re-evaluation. Of the in all 15 cases initially classified as no myocarditis or insufficient information, 7 were after re-evaluation re-classified as probable or possible myocarditis. This re-classification was mostly due to substantial variability in electrocardiogram interpretation. CONCLUSION: This validation of register-based diagnoses of myocarditis by manual patient record review confirmed the register diagnosis in 96% of cases and had high interrater reliability. Reclassification had only a minor impact on the incidence rate ratios for myocarditis following COVID-19 vaccination. Open Academia 2023-05-11 /pmc/articles/PMC10202079/ /pubmed/37223633 http://dx.doi.org/10.48101/ujms.v128.9290 Text en © 2023 The Author(s). Published by Upsala Medical Society. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Gedeborg, Rolf Holm, Lennart Feltelius, Nils Sundström, Anders Eggers, Kai M Nurminen, Marja-Leena Grünewald, Maria Pihlström, Nicklas Zethelius, Björn Ljung, Rickard Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines |
title | Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines |
title_full | Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines |
title_fullStr | Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines |
title_full_unstemmed | Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines |
title_short | Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines |
title_sort | validation of myocarditis diagnoses in the swedish patient register for analyses of potential adverse reactions to covid-19 vaccines |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202079/ https://www.ncbi.nlm.nih.gov/pubmed/37223633 http://dx.doi.org/10.48101/ujms.v128.9290 |
work_keys_str_mv | AT gedeborgrolf validationofmyocarditisdiagnosesintheswedishpatientregisterforanalysesofpotentialadversereactionstocovid19vaccines AT holmlennart validationofmyocarditisdiagnosesintheswedishpatientregisterforanalysesofpotentialadversereactionstocovid19vaccines AT felteliusnils validationofmyocarditisdiagnosesintheswedishpatientregisterforanalysesofpotentialadversereactionstocovid19vaccines AT sundstromanders validationofmyocarditisdiagnosesintheswedishpatientregisterforanalysesofpotentialadversereactionstocovid19vaccines AT eggerskaim validationofmyocarditisdiagnosesintheswedishpatientregisterforanalysesofpotentialadversereactionstocovid19vaccines AT nurminenmarjaleena validationofmyocarditisdiagnosesintheswedishpatientregisterforanalysesofpotentialadversereactionstocovid19vaccines AT grunewaldmaria validationofmyocarditisdiagnosesintheswedishpatientregisterforanalysesofpotentialadversereactionstocovid19vaccines AT pihlstromnicklas validationofmyocarditisdiagnosesintheswedishpatientregisterforanalysesofpotentialadversereactionstocovid19vaccines AT zetheliusbjorn validationofmyocarditisdiagnosesintheswedishpatientregisterforanalysesofpotentialadversereactionstocovid19vaccines AT ljungrickard validationofmyocarditisdiagnosesintheswedishpatientregisterforanalysesofpotentialadversereactionstocovid19vaccines |